128 related articles for article (PubMed ID: 20005117)
21. Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition.
Qvigstad E; Moltzau LR; Aronsen JM; Nguyen CH; Hougen K; Sjaastad I; Levy FO; Skomedal T; Osnes JB
Cardiovasc Res; 2010 Mar; 85(4):763-72. PubMed ID: 19900965
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
26. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Manallack DT; Hughes RA; Thompson PE
J Med Chem; 2005 May; 48(10):3449-62. PubMed ID: 15887951
[No Abstract] [Full Text] [Related]
27. Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.
Wang G; Liu Z; Chen T; Wang Z; Yang H; Zheng M; Ren J; Tian G; Yang X; Li L; Li J; Suo J; Zhang R; Jiang X; Terrett NK; Shen J; Xu Y; Jiang H
J Med Chem; 2012 Dec; 55(23):10540-50. PubMed ID: 23137303
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and pharmacological evaluation of 4-[2-alkylthio-5(4)-(4-substitutedphenyl)imidazole-4(5)yl]benzenesulfonamides as selective COX-2 inhibitors.
Salimi M; Ghahremani MH; Naderi N; Amini M; Salimi E; Amanlou M; Abdi K; Salehi R; Shafiee A
Acta Pharmacol Sin; 2007 Aug; 28(8):1254-60. PubMed ID: 17640491
[TBL] [Abstract][Full Text] [Related]
29. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F
J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176
[TBL] [Abstract][Full Text] [Related]
30. Expression of cyclic nucleotide phosphodiesterase 3A in isolated rat submandibular acini.
Shimizu K; Murata T; Hiramoto K; Sugiyama T; Nakagawa T; Manganiello VC; Tagawa T
Arch Oral Biol; 2006 Feb; 51(2):83-8. PubMed ID: 16102722
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
Onda K; Shiraki R; Ogiyama T; Yokoyama K; Momose K; Katayama N; Orita M; Yamaguchi T; Furutani M; Hamada N; Takeuchi M; Okada M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2008 Dec; 16(23):10001-12. PubMed ID: 18952447
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).
Hughes RO; Rogier DJ; Jacobsen EJ; Walker JK; Macinnes A; Bond BR; Zhang LL; Yu Y; Zheng Y; Rumsey JM; Walgren JL; Curtiss SW; Fobian YM; Heasley SE; Cubbage JW; Moon JB; Brown DL; Acker BA; Maddux TM; Tollefson MB; Mischke BV; Owen DR; Freskos JN; Molyneaux JM; Benson AG; Blevis-Bal RM
J Med Chem; 2010 Mar; 53(6):2656-60. PubMed ID: 20196613
[TBL] [Abstract][Full Text] [Related]
33. N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.
Westaway SM; Chung YK; Davis JB; Holland V; Jerman JC; Medhurst SJ; Rami HK; Stemp G; Stevens AJ; Thompson M; Winborn KY; Wright J
Bioorg Med Chem Lett; 2006 Sep; 16(17):4533-6. PubMed ID: 16806913
[TBL] [Abstract][Full Text] [Related]
34. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
35. Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
Lacombe P; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Gallant M; Girard Y; Huang Z; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini JA; Masson P; Nicholson DW; Nicoll-Griffith DA; Salem M; Styhler A; Young RN
Bioorg Med Chem Lett; 2009 Sep; 19(17):5266-9. PubMed ID: 19640717
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
[TBL] [Abstract][Full Text] [Related]
37. 6-Nitrobenzimidazole derivatives: potential phosphodiesterase inhibitors: synthesis and structure-activity relationship.
Khan KM; Shah Z; Ahmad VU; Ambreen N; Khan M; Taha M; Rahim F; Noreen S; Perveen S; Choudhary MI; Voelter W
Bioorg Med Chem; 2012 Feb; 20(4):1521-6. PubMed ID: 22264761
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Wang L; Wang GT; Wang X; Tong Y; Sullivan G; Park D; Leonard NM; Li Q; Cohen J; Gu WZ; Zhang H; Bauch JL; Jakob CG; Hutchins CW; Stoll VS; Marsh K; Rosenberg SH; Sham HL; Lin NH
J Med Chem; 2004 Jan; 47(3):612-26. PubMed ID: 14736242
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
Kumar S; Bawa S; Drabu S; Gupta H; Machwal L; Kumar R
Eur J Med Chem; 2011 Feb; 46(2):670-5. PubMed ID: 21194811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
